Novartis $NOVN

Recent News (20)

• Novartis ends Fabhalta trial for lupus kidney disease Investing.com · 19 Oct 2026 Novartis ends Fabhalta trial for lupus kidney disease
• Novartis ends mid-stage trial for Fabhalta in lupus nephritis Investing.com · 16 Oct 2026 Novartis ends mid-stage trial for Fabhalta in lupus nephritis
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS PR Newswire · 08 Oct 2026 NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dani…
• Novartis to present 46 MS abstracts; stock after-hours at EUR 128.88, plus 3.43 percent AD HOC NEWS · 07 Oct 2026 Novartis to present 46 MS abstracts; stock after-hours at EUR 128.88, plus 3.43 percent  AD HOC NEWS
• Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) GlobeNewswire · 07 Oct 2026 Basel, October 7, 2026 – Novartis announced today that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi…
• Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 GlobeNewswire · 07 Oct 2026 Basel, October 07, 2026 – Novartis will present new data from its multiple sclerosis (MS) portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-br…
• Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure Yahoo! Finance Canada · 12 Sep 2026 Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure  Yahoo! Finance Canada
• Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure Yahoo Finance · 12 Sep 2026 Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
• Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure Yahoo Finance · 12 Sep 2026 Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure  Yahoo Finance
• Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More Yahoo Finance · 10 Sep 2026 Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
• Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more CNBC · 10 Sep 2026 Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more  CNBC
• Amgen Stock: Buy The Novartis-Driven Selloff (Rating Upgrade) (NASDAQ:AMGN) Seeking Alpha · 10 Sep 2026 Amgen Stock: Buy The Novartis-Driven Selloff (Rating Upgrade) (NASDAQ:AMGN)  Seeking Alpha
• Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade) Seeking Alpha · 10 Sep 2026 Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)  Seeking Alpha
• Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector? Yahoo Finance · 09 Sep 2026 Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
• Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension TIKR.com · 09 Sep 2026 Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension  TIKR.com
• AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market Yahoo Finance · 08 Sep 2026 AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market
• AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market Barron's · 08 Sep 2026 AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market  Barron's
• Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) Failure - Amgen (NASDAQ:AMGN) Benzinga · 08 Sep 2026 Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) Failure - Amgen (NASDAQ:AMGN)  Benzinga
• Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% Yahoo Finance · 08 Sep 2026 Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
• Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers marketscreener.com · 08 Sep 2026 Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers  marketscreener.com